Department of Health Science, California State University, Fullerton, CA, USA.
Prostate. 2010 Jun 1;70(8):906-15. doi: 10.1002/pros.21125.
Androgens and growth factors are thought to be associated with prostate cancer risk, although past research has produced mixed results.
We conducted a nested case-control study of biomarkers of prostate cancer risk within the Multiethnic Cohort. We compared prediagnostic levels of testosterone, dihydrotestosterone (DHT), sex hormone-binding globulin (SHBG), 3alpha-androstanediol glucuronide (3alpha-diol G), insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein 1 (IGFBP-1), and IGFBP-3 in serum from 467 incident prostate cancer cases and 934 cancer-free controls. Controls were matched to the cases on geographic site (HI, LA), ethnicity, age at specimen collection (+/-1 year), date (+/-1 month) and time of day (+/-2 hr) of sample collection, and fasting status (<6, 6-7, 8-9, >10 hr). Multivariate conditional logistic regression models were used to compute adjusted odds ratios (ORs) and 95% confidence intervals (CIs).
Serum concentrations of testosterone, DHT, SHBG, 3alpha-diol G, IGF-I, IGF-II, IGFBP-1, and IGFBP-3 were not associated with risk of prostate cancer. Tests for trend of quartiles of serum concentrations also did not show any association. Results were relatively unchanged for men with advanced prostate cancer and their matched controls. However, the follow-up period was relatively short (mean of 1.9 years). Analysis by ethnic group showed an increased risk for Latino men in the second (OR = 3.67, 95% CI: 1.63-8.24) and third (OR = 2.96, 95% CI: 1.19-7.40) tertiles of IGF-I serum levels compared with the first tertile.
The suggested increased risk for IGF-I in Latino men merits further study, with greater statistical power.
雄激素和生长因子被认为与前列腺癌的风险有关，尽管过去的研究结果喜忧参半。
我们在多民族队列中进行了一项基于前列腺癌风险生物标志物的巢式病例对照研究。我们比较了 467 例前列腺癌新发病例和 934 例无癌症对照者的血清中睾丸酮、二氢睾丸酮（DHT）、性激素结合球蛋白（SHBG）、3α-雄烷二醇葡萄糖醛酸（3α-diol G）、胰岛素样生长因子 I（IGF-I）、胰岛素样生长因子 II（IGF-II）、胰岛素样生长因子结合蛋白 1（IGFBP-1）和胰岛素样生长因子结合蛋白 3（IGFBP-3）的预诊断水平。对照组按病例的地理区域（HI、LA）、种族、采集标本的年龄（相差 1 岁）、采集日期（相差 1 个月）和采集时间（相差 2 小时）以及空腹状态（<6、6-7、8-9、>10 小时）与病例相匹配。采用多变量条件逻辑回归模型计算调整后的比值比（OR）和 95%置信区间（CI）。
血清睾丸酮、DHT、SHBG、3α-diol G、IGF-I、IGF-II、IGFBP-1 和 IGFBP-3 浓度与前列腺癌风险无关。按四分位数血清浓度的趋势检验也未显示任何关联。对于晚期前列腺癌患者及其匹配对照者，结果变化不大。然而，随访期相对较短（平均 1.9 年）。按种族组分析显示，与 IGF-I 血清水平第一四分位相比，第二（OR=3.67，95%CI：1.63-8.24）和第三（OR=2.96，95%CI：1.19-7.40）四分位的拉丁裔男性发生前列腺癌的风险增加。
拉丁裔男性 IGF-I 水平升高的风险增加，需要进一步研究，以获得更大的统计学效力。
